
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Raulo Frear, PharmD, general manager of OmedaRx, discusses the ramifications of biosimilars hitting the US market.
Raulo Frear, PharmD, general manager of OmedaRx, discusses the ramifications of biosimilars hitting the US market.




